阿米奥达龙可以防止心力衰竭患者的波浪前尾相互作用:一项in silico研究
Richard A Gray1, Michael R Franz2,3
1Division of Biomedical Physics, Office of Science and Engineering Laboratories, Center for Devices and Radiological Health, Food and Drug Administration, Silver Spring, Maryland, United States.
American journal of physiology. Heart and circulatory physiology
|September 1, 2023
概括
阿米奥达龙 (AM) 通过其通道效应增加后反极化折射率 (PRR) 来预防心力衰竭 (HF) 中的复发性心律失常. 这项研究模拟了AMAM的模型.
科学领域:
- 计算生物学 计算生物学
- 心血管生理学心血管生理学
- 药理学 药理学是指药理学的学科.
背景情况:
- 阿米奥达龙 (AM) 是一种有效的抗心律失常药物,用于心力衰竭 (HF) 患者的心室心律失常.
- 艾米表现出III类和I类抗失律性质,但其防止HF重新进入的确切机制尚不清楚.
研究的目的:
- 测试AM通过其I类通道效应诱导后反极化折射性 (PRR) 来防止HF再入感应的假设.
- 开发和利用一个包含HF和AM效应的人类行动潜力模型来研究这种机制.
主要方法:
- 扩展了人类行动潜力模型,以单独模拟HF和AM效应,并与人类组织和临床数据进行校准.
- 结合HF和AM模型,在各种动能电位持续度梯度下模拟2D模型中的再入感应.
- 研究了在AM的抗失律效应中不活化道恢复的作用.
主要成果:
- 在模拟显示AM增加PRR和降低起飞潜在高度.
- 在所有HF模型中诱导了重新进入,但在24个HF + AM模型中的23个中被阻止.
- 在AM的存在下恢复正常的通道恢复失活,允许重新进入诱导.
结论:
- 计算测试表明,慢性AM治疗在编程电刺激期间可以防止HF患者的再进入诱导.
- 这种预防归因于AM的I类效应,即诱导后反极化折射性.
- 一个新型模型阐明了AM在预防高频率患者复发性心律失常的机制.
相关概念视频
01:12Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers
1.0K
Class III antiarrhythmic drugs are a group of medications that can prolong action potentials in the heart. They achieve this by blocking potassium channels or enhancing inward currents from sodium channels. However, these drugs have a unique property of "reverse use-dependence," which is most pronounced at slower heart rates and can lead to torsades de pointes—a specific type of arrhythmia. However, it is essential to note that excessive QT interval prolongation—a measure of...
1.0K
01:26Heart Failure Drugs: Inotropic Agents
618
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
618
01:29Heart Failure II: Pathophysiology
15
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
15
01:28Mechanism of Cardiac Arrhythmias
950
Arrhythmias are irregular heart rhythms occurring when the heart's electrical impulses become abnormal. These disturbances can lead to various symptoms, depending on their severity and the underlying cause. Some common factors contributing to arrhythmias include hypoxia, ischemia, electrolyte imbalances, excessive catecholamine exposure, drug toxicity, and muscle overstretching. Arrhythmias can be classified into two main types based on the rate and site of origin of abnormal heart rhythms.
950
01:20Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers
875
Class IV antiarrhythmic drugs, such as verapamil and diltiazem, block calcium channels. They primarily affect the heart, slowing the conduction in calcium-dependent tissues like the SA and AV nodes. These drugs manage reentrant supraventricular tachycardia (SVT) and reduce ventricular rate in atrial flutter/fibrillation.
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
875
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
463
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
463